Gynecologic Oncology | Specialty

Social Determinants of Health Linked With Varying Cervical Cancer Rates in the US

March 16th 2024

Social determinants of health were associated with geographical variations in the rates of cervical cancer in the United States.

Pembrolizumab Plus Concurrent CRT Meets OS End Point in High-Risk, Locally Advanced Cervical Cancer

March 15th 2024

The KEYNOTE-A18 trial met its coprimary end point of improved OS with pembrolizumab plus concurrent chemoradiotherapy in high-risk cervical cancer.

Dr Franco on the Integration of Immunotherapy Treatment in Endometrial Cancer

March 14th 2024

Idalid Franco, MD, MPH, discusses the use of radiation therapy and immunomodulatory agents in the treatment of endometrial cancer.

Modesitt Spotlights the Latest ADC Breakthroughs in Gynecologic Oncology

March 11th 2024

Susan C. Modesitt, MD, FACOG, FACS, sheds light on the latest research with antibody-drug conjugates across gynecologic cancers.

Dr Miller on the Importance of Patient Advocacy in Gynecologic Oncology

March 8th 2024

Eirwen M. Miller, MD, discusses the importance of advocating for women in gynecologic oncology on International Women’s Day.

Empowering Women in Oncology and Beyond on International Women’s Day

March 8th 2024

Eirwen M. Miller, MD, discusses her experience in the oncology field and the importance of ensuring gender is not a defining quality for oncologists.

ABSK061 Demonstrates Safety, Preliminary Efficacy in FGFR2/3+ Advanced Solid Tumors

March 7th 2024

ABSK061 was well tolerated and elicited responses in patients with advanced solid tumors harboring FGFR2/3 alterations.

Modesitt Reflects on the Art of Treatment Selection Amidst Expansion of Targeted and Immunotherapies in Gynecologic Oncology

March 6th 2024

NICE Recommends Dostarlimab Plus Chemo in MSI-High/dMMR Endometrial Cancer

March 5th 2024

The National Institute for Health and Care Excellence recommends the approval of dostarlimab plus chemotherapy for advanced/recurrent endometrial cancer.

Discordant dMMR/IHC Status Correlates With Improved Treatment Outcomes in CRC and Endometrial Cancer

February 27th 2024

Patients with mismatch repair–deficient, immunohistochemistry-intact colorectal cancer or endometrial cancer benefit from immune checkpoint inhibitors.

Revisit Every OncLive On Air Episode From January 2024

February 26th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

State of the Science Summit - Gynecologic Cancers: Chaired by Susan C. Modesitt, MD, FACOG, FACS

February 21st 2024

State of the Science Summit - Gynecologic Cancers: Chaired by Susan C. Modesitt, MD, FACOG, FACS

FDA Grants Priority Review to Pembrolizumab Plus Chemotherapy in Endometrial Cancer

February 20th 2024

The sBLA for pembrolizumab plus chemotherapy in endometrial cancer has been granted priority review by the FDA.

Dr Hagensee on Strategies For Cervical Cancer Prevention

February 14th 2024

Michael Hagensee, MD, PhD, discusses strategies for cervical cancer prevention and ongoing research investigating barriers to cervical cancer treatment.

Phase 3 Randomized Trials: Expanding Clinically Meaningful Analysis Beyond the Stated Goals

February 9th 2024

The foundation of physician recommendations and medical/regulatory policy will be guided by the outcomes of published clinical research.

Complementary NGS Improves dMMR Detection With IHC in CRC and Endometrial Cancer

February 8th 2024

Amin Nassar, MD, and Elias Bou Farhat, MD, spotlight a study evaluating the accuracy and sensitivity of NGS mutation signature in assessing MMR status vs IHC testing.

Future Perspectives on HER2 ADCs in Gynecological Cancer

February 8th 2024

Martin Dietrich, MD, PhD, and Ritu Salani, MD, share their outlook on the future roles of HER2-directed ADCs in gynecological cancers and other solid tumors, highlighting the necessity for additional research to provide further understanding in these areas.

Expert Insights on HER2 Testing in Gynecological Cancers

February 8th 2024

Ritu Salani, MD, provides expert insights regarding HER2 testing in patients with gynecological cancers, emphasizing the need for standardization in testing practices and greater clarity surrounding the incidence of HER2 positivity across gynecological cancers.

State of the Science Summit - Gynecologic Cancers: Chaired by Abdulrahman Sinno, MD

February 6th 2024

State of the Science Summit - Gynecologic Cancers: Chaired by Abdulrahman Sinno, MD.

EMA Validates MAA for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

February 2nd 2024

The MAA seeking the approval of tisotumab vedotin in select patients with recurrent or metastatic cervical cancer has been validated by the EMA.